Detalhe da pesquisa
1.
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
Mol Cancer Ther
; 6(12 Pt 1): 3158-68, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18089710
2.
PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
Clin Cancer Res
; 12(13): 4080-9, 2006 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16818708
3.
Wild rats as monitors of environmental lead contamination in the urban area of Milan, Italy.
Environ Pollut
; 117(2): 255-9, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-11916039
4.
Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
Epigenetics
; 8(6): 656-65, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23771052
5.
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
PLoS One
; 8(3): e58424, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23520509
6.
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
Exp Hematol
; 38(4): 259-269.e2, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20167248
7.
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Clin Cancer Res
; 15(21): 6694-701, 2009 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19825950
8.
Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials.
Prostate
; 67(4): 396-404, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17187397